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The relative effectiveness of second-generation (atypical) antipsychotic drugs as com-
pared with that of older agents has been incompletely addressed, though newer agents
are currently used far more commonly. We compared a first-generation antipsychotic,




A total of 1493 patients with schizophrenia were recruited at 57 U.S. sites and random-
ly assigned to receive olanzapine (7.5 to 30 mg per day), perphenazine (8 to 32 mg per
day), quetiapine (200 to 800 mg per day), or risperidone (1.5 to 6.0 mg per day) for up
to 18 months. Ziprasidone (40 to 160 mg per day) was included after its approval by the
Food and Drug Administration. The primary aim was to delineate differences in the




Overall, 74 percent of patients discontinued the study medication before 18 months
(1061 of the 1432 patients who received at least one dose): 64 percent of those assigned
to olanzapine, 75 percent of those assigned to perphenazine, 82 percent of those as-
signed to quetiapine, 74 percent of those assigned to risperidone, and 79 percent of
those assigned to ziprasidone. The time to the discontinuation of treatment for any
cause was significantly longer in the olanzapine group than in the quetiapine (P<0.001)
or risperidone (P=0.002) group, but not in the perphenazine (P=0.021) or ziprasidone
(P=0.028) group. The times to discontinuation because of intolerable side effects were
similar among the groups, but the rates differed (P=0.04); olanzapine was associated
with more discontinuation for weight gain or metabolic effects, and perphenazine




The majority of patients in each group discontinued their assigned treatment owing to
inefficacy or intolerable side effects or for other reasons. Olanzapine was the most ef-
fective in terms of the rates of discontinuation, and the efficacy of the conventional anti-
psychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and
ziprasidone. Olanzapine was associated with greater weight gain and increases in mea-
sures of glucose and lipid metabolism.
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ntipsychotic drugs have become
 
the cornerstone of treatment for schizo-
phrenia. The first-generation “conven-
tional” antipsychotic drugs are high-affinity an-
tagonists of dopamine D2 receptors that are most
effective against psychotic symptoms but have high
rates of neurologic side effects, such as extrapyrami-





of second-generation, or “atypical,” antipsychotic





atypical agents differ pharmacologically from previ-
ous antipsychotic agents in their lower affinity for
dopamine D2 receptors and greater affinities for
















































Although studies indicated that the atypical
drugs are similar to the conventional drugs in reduc-
ing psychotic symptoms and produce few neuro-
logic effects, the evidence of their superior efficacy





exception of clozapine, which repeatedly has been
effective in patients whose condition is refractory to
treatment with other types of agents but has severe




 The newer agents
appear more efficacious than conventional drugs
in reducing negative symptoms (e.g., lack of emo-
tion, interest, and expression), possibly owing to the




 or other sec-
ondary causes of negative symptoms (e.g., depres-




The results of studies of the effects of treatment on





 The ability of atypical agents
to prevent relapse and their effects on social and
vocational functioning, quality of life, long-term





The safety advantages of the atypical drugs have










 Nevertheless, these medications are






costs. In the wake of this trend, questions have
been raised about the clinical advantages and cost
effectiveness of the atypical drugs. We report the
primary outcomes of a double-blind, active-control
clinical trial sponsored by the National Institute of
Mental Health (NIMH) that was designed to com-





study setting and design
 
The Clinical Antipsychotic Trials of Intervention
Effectiveness (CATIE) study was initiated by the
NIMH to compare the effectiveness of antipsychotic





 The protocol was made
available to the public for comment, and a commit-
tee of scientific experts, health care administrators,
and consumer advocates critiqued the study under
the auspices of the NIMH. The study was conduct-
ed between January 2001 and December 2004 at 57
clinical sites in the United States (16 university clin-
ics, 10 state mental health agencies, 7 Veterans Af-
fairs medical centers, 6 private nonprofit agencies,
4 private-practice sites, and 14 mixed-system sites).
Patients were initially randomly assigned to receive
olanzapine, perphenazine, quetiapine, or risperi-
done under double-blind conditions and followed
for up to 18 months or until treatment was discon-
tinued for any reason (phase 1). (Ziprasidone was
approved for use by the Food and Drug Adminis-
tration [FDA] after the study began and was added
to the study in January 2002 in the form of an iden-
tical-appearing capsule containing 40 mg.) Patients
whose assigned treatment was discontinued could









Eligible patients were 18 to 65 years of age; had re-
ceived a diagnosis of schizophrenia, as determined
on the basis of the Structured Clinical Interview of
the 
 
Diagnostic and Statistical Manual of Mental Disorders,
 
fourth edition; and were able to take oral antipsy-
chotic medication, as determined by the study doc-
tor. Patients were excluded if they had received a
diagnosis of schizoaffective disorder, mental retar-
dation, or other cognitive disorders; had a history
of serious adverse reactions to the proposed treat-
ments; had had only one schizophrenic episode;
had a history of treatment resistance, defined by the
persistence of severe symptoms despite adequate
trials of one of the proposed treatments or prior
treatment with clozapine; were pregnant or breast-
feeding; or had a serious and unstable medical
condition.
The study was approved by the institutional re-
view board at each site, and written informed con-
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Identical-appearing capsules contained olanzap-
ine (Zyprexa, Eli Lilly) (7.5 mg), quetiapine (Sero-
quel, AstraZeneca) (200 mg), risperidone (Risper-
dal, Janssen Pharmaceutica) (1.5 mg), perphenazine
(Trilafon, Schering-Plough, at the time of the study)
(8 mg), or (after January 2002) ziprasidone (Geo-
don, Pfizer) (40 mg). The packaging was done by
Quintiles. The dose of medications was flexible,
ranging from one to four capsules daily, and was
based on the study doctor’s judgment. Overlap in
the administration of the antipsychotic agents that
patients received before study entry was permitted
for the first four weeks after randomization to allow
a gradual transition to study medication. Concom-
itant medications were permitted throughout the
trial, except for additional antipsychotic agents.
Patients had monthly visits with study doctors.
Because of product labeling, quetiapine and
ziprasidone are given twice daily and olanzapine,
perphenazine, and risperidone once daily. To pro-
tect blinding, half the patients randomly assigned
to perphenazine, olanzapine, and risperidone were
assigned to twice-daily dosing and half to once-
daily dosing. To minimize initial side effects, pa-
tients assigned to quetiapine began treatment by
receiving one 100-mg capsule on days 1 and 2, one
twice daily on day 3, and one for the first dose of
day 4. All patients assigned to twice-daily dosing
received five identical-appearing capsules to begin
treatment. Patients with current tardive dyskine-
sia could enroll, but the randomization scheme





We hypothesized that there would be significant
differences in the overall effectiveness of olanza-
pine, perphenazine, quetiapine, risperidone, and
ziprasidone in treating schizophrenia that reflected
variations in efficacy and tolerability. The primary
outcome measure was the discontinuation of treat-
ment for any cause, a discrete outcome selected be-
cause stopping or changing medication is a frequent
occurrence and major problem in the treatment of
schizophrenia. In addition, this measure integrates
patients’ and clinicians’ judgments of efficacy, safe-
ty, and tolerability into a global measure of effec-
tiveness that reflects their evaluation of therapeutic
benefits in relation to undesirable effects. The key
secondary outcomes were the specific reasons for
the discontinuation of treatment (e.g., inefficacy or
intolerability owing to side effects such as weight
gain, extrapyramidal signs, or sedation as judged
by the study doctor). Additional secondary efficacy
outcomes included scores on the Positive and Neg-
ative Syndrome Scale (PANSS) and the Clinical
Global Impressions (CGI) Scale. PANSS scores can
range from 30 to 210, with higher scores indicat-
ing more severe psychopathology. Scores for the
CGI Scale can range from 1 to 7, with higher scores
indicating greater severity of illness. Secondary safe-
ty and tolerability outcomes, which were evaluated
at months 1, 3, 6, 9, 12, 15, and 18, included the in-
cidence of serious adverse events, the incidence of
adverse events during treatment, the incidence of
neurologic side effects, and changes in weight, elec-




Randomized patients who received at least one
dose of study medication made up the intention-to-
treat population. Two hundred thirty-one patients
with tardive dyskinesia were excluded from random
assignment to perphenazine. Ziprasidone was add-
ed to the trial after approximately 40 percent of
the patients had been enrolled. Consequently, com-
parisons involving the perphenazine group were
limited to patients without tardive dyskinesia, and
comparisons involving the ziprasidone group were
limited to the cohort of patients who underwent
randomization after ziprasidone was added (the
ziprasidone cohort). In general, the trial had a sta-
tistical power of 85 percent to identify an absolute
difference of 12 percent in the rates of discontinu-
ation between two atypical agents; however, it had
a statistical power of 76 percent for comparisons
involving perphenazine and of 58 percent for com-
parisons involving ziprasidone.
We used Kaplan–Meier survival curves to esti-
mate the time to the discontinuation of treatment.






fied according to site, with adjustment for whether
the patient had had an exacerbation of schizophre-
nia in the preceding three months and tardive dys-
kinesia status (for models excluding perphena-
zine). Sites with 15 or fewer patients were grouped
according to the sites’ health care systems.
The overall difference among the olanzapine,
quetiapine, risperidone, and perphenazine groups
was evaluated with the use of a test with 3 degrees
of freedom (df ). If the difference was significant at
a P value of less than 0.05, the three atypical-drug
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groups were compared with each other by means
of step-down or closed testing, with a P value of
less than 0.05 considered to indicate statistical sig-
nificance. Each group was then compared with the
perphenazine group by means of a Hochberg ad-





resulting P value was compared with a value of 0.017
(0.05 ÷ 3). The ziprasidone group was directly com-
pared with the other three atypical-drug groups and
the perphenazine group within the ziprasidone co-
hort by means of a Hochberg adjustment for four
pairwise comparisons. The smallest resulting P val-
ue was compared with a value of 0.013 (0.05 ÷ 4).
Successful treatment time was defined as the
number of months of treatment during phase 1 in
which patients had a CGI Scale score of at least 3
(mildly ill) or a score of 4 (moderately ill) with an
improvement of at least two points from baseline.
Treatment groups were compared with use of pro-
portional-hazards regression.
A sensitivity analysis of the Cox model for the
discontinuation of treatment for any cause evaluat-
ed the effects of potentially important baseline co-
variates and their interaction with the treatment
group.
The PANSS total scores and CGI Scale scores
over time were compared among the groups with
the use of a mixed model including the same fixed
covariates as for the time to discontinuation, plus
baseline value, time, the interaction between treat-
ment and time, and the interaction between base-
line value and time. Time was classified into months
(1, 3, 6, 9, 12, 15, and 18). The results of assess-
ments made at the end of phase 1 were assigned to
the next interval. The correlation of the repeated
measures within each patient was modeled with
the use of a random subject intercept and an un-
structured covariance matrix.
The study was funded by the NIMH. The pharma-
ceutical companies whose drugs were included in
the study donated drug supplies, and each provid-
ed advice on the dose of its own drug; they were
otherwise not involved in the design of the study,
analyses, or interpretation of results. The manu-
script was written solely by the listed authors.
 
characteristics and disposition 
of patients
 
Table 1 shows the baseline demographic and clini-
cal characteristics of the patients. Figure 1 depicts
the enrollment, randomization, and follow-up of
study patients; 1493 patients were enrolled in the
study and randomly assigned to treatment. All data
from one site (33 patients) were excluded before
analysis, owing to concern about the integrity of data
from that site before the end of the study and before
unblinding. The mean modal doses were 20.1 mg
per day for olanzapine, 20.8 mg per day for per-
phenazine, 543.4 mg per day for quetiapine, 3.9 mg
per day for risperidone, and 112.8 mg per day for
ziprasidone (Table 2). Seventy-four percent of pa-
tients in the intention-to-treat analysis (1061 of
1432) discontinued their assigned treatment in




The time to the discontinuation of treatment for
any cause was longer in the olanzapine group than
in the quetiapine group (hazard ratio, 0.63; P<0.001),
the risperidone group (hazard ratio, 0.75; P=0.002),
or the perphenazine group (hazard ratio, 0.78;
P=0.021) (Table 2). However, the difference be-
tween the olanzapine group and the perphenazine
group was not significant after adjustment for mul-
tiple comparisons (required P value, ≤0.017). With-
in the cohort of 889 patients who underwent ran-
domization after ziprasidone was added to the trial,
those receiving olanzapine had a longer interval be-
fore discontinuing treatment for any cause than
did those in the ziprasidone group (hazard ratio,
0.76; P=0.028). However, this difference was not
significant after adjustment for multiple compari-
sons (required P value, ≤0.013).
The time to the discontinuation of treatment for
lack of efficacy was longer in the olanzapine group
than in the perphenazine group (hazard ratio, 0.47;
P<0.001), the quetiapine group (hazard ratio, 0.41;
P<0.001), the risperidone group (hazard ratio,
0.45; P<0.001), or the ziprasidone group (hazard
ratio, 0.59; P=0.026), but the difference between
the olanzapine and ziprasidone groups was not sig-
nificant after adjustment for multiple comparisons
(required P value, ≤0.013) (Table 2). There were no
significant differences between groups in time un-
til discontinuation owing to intolerable side effects
(P=0.054). The time until discontinuation owing
to the patient’s decision (i.e., the patient indepen-
dently chose to stop treatment) was similar to that
for discontinuation for any cause (Table 2).
The duration of successful treatment was sig-
nificantly longer in the olanzapine group than in
the quetiapine group (hazard ratio, 0.53; P<0.001),
the risperidone group (hazard ratio, 0.69; P=0.002),
or the perphenazine group (hazard ratio, 0.73;
results
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* Plus–minus values are means ±SD. Because of rounding, percentages may not sum to 100. SCID denotes Structured Clinical Interview for DSM-IV.
† Patients with tardive dyskinesia were excluded from the perphenazine group.
‡ Race was self-reported. “Other” includes American Indian or Alaska Native (less than 1 percent of patients), Asian (2 percent), Native Hawaiian 
or other Pacific Islander (less than 1 percent), and two or more races (2 percent). Percentages are based on the number of patients with data 
available: 336 in the olanzapine group, 337 in the quetiapine group, 341 in the risperidone group, 261 in the perphenazine group, and 183 in 
the ziprasidone group.
§ This category includes patients who were widowed, divorced, or separated. 
¶ Percentages are based on the number of patients with data available: 330 in the olanzapine group, 328 in the quetiapine group, 336 in the ris-
peridone group, 259 in the perphenazine group, and 182 in the ziprasidone group.
¿ Scores on the Positive and Negative Syndrome Scale (PANSS) for schizophrenia can range from 30 to 210, with higher scores indicating 
more severe psychopathology.
** The CGI severity score can range from 1 to 7, with higher scores indicating greater severity of illness.
††Percentages for baseline medications are based on the number of patients with data on concomitant medications: 333 in the olanzapine 
 
group, 333 in the quetiapine group, 340 in the risperidone group, 259 in the perphenazine group, and 184 in the ziprasidone group.
 
















Age — yr 40.8±10.8 40.9±11.2 40.6±11.3 40.0±11.1 40.1±11.0 40.6±11.1
Sex — no. (%)
Male 244 (73) 255 (76) 253 (74) 199 (76) 129 (70) 1080 (74)
Female 92 (27) 82 (24) 88 (26) 62 (24) 56 (30) 380 (26)
Race — no. (%)‡
White 196 (58) 213 (63) 204 (60) 152 (58) 109 (60) 874 (60)
Black 119 (35) 114 (34) 122 (36) 93 (36) 65 (36) 513 (35)
Other 21 (6) 10 (3) 15 (4) 16 (6) 9 (5) 71 (5)
Spanish, Hispanic, or Latino ethnicity — no. (%) 42 (12) 48 (14) 38 (11) 24 (9) 18 (10) 170 (12)
Education — yr 12.2±2.2 12.1±2.4 12.0±2.2 12.1±2.1 12.0±2.5 12.1±2.3
Marital status — no. (%)
Married 36 (11) 34 (10) 37 (11) 43 (16) 17 (9) 167 (11)
Previously married§ 105 (31) 90 (27) 101 (30) 68 (26) 61 (33) 425 (29)
Never married 195 (58) 213 (63) 203 (60) 150 (57) 107 (58) 868 (59)
Unemployed — no. (%)¶ 281 (85) 274 (84) 288 (86) 219 (85) 155 (85) 1217 (85)
Exacerbation in previous 3 mo — no. (%) 90 (27) 89 (26) 95 (28) 68 (26) 60 (32) 402 (28)
PANSS total score¿ 76.1±18.2 75.7±16.9 76.4±16.6 74.3±18.1 75.4±18.6 75.7±17.6




Age at 1st treatment for any behavioral 
or emotional problem — yr
24.1±9.0 23.6±8.1 23.7±9.3 24.5±8.6 24.1±9.7 24.0±8.9
Years since 1st antipsychotic medication 
prescribed
14.5±11.0 14.6±10.3 14.8±10.7 13.8±11.0 14.0±10.5 14.4±10.7
 
SCID diagnosis in past 5 yr — no. (%)
 
Depression 86 (26) 84 (25) 104 (30) 71 (27) 60 (32) 405 (28)
Alcohol dependence or alcohol abuse 74 (22) 81 (24) 92 (27) 74 (28) 37 (20) 358 (25)
Drug dependence or drug abuse 86 (26) 95 (28) 110 (32) 74 (28) 57 (31) 422 (29)
Obsessive–compulsive disorder 10 (3) 22 (7) 21 (6) 12 (5) 8 (4) 73 (5)
Other anxiety disorder 44 (13) 46 (14) 52 (15) 29 (11) 28 (15) 199 (14)
 
Baseline antipsychotic medications — no. (%)††
 
Olanzapine alone 78 (23) 69 (20) 76 (22) 58 (22) 41 (22) 322 (22)
Quetiapine alone 24 (7) 17 (5) 22 (6) 15 (6) 17 (9) 95 (7)
Risperidone alone 57 (17) 59 (18) 63 (18) 64 (25) 32 (17) 275 (19)
Any combination including olanzapine, quetia-
pine, or risperidone
31 (9) 32 (10) 33 (10) 21 (8) 8 (4) 95 (7)
All others 52 (15) 58 (17) 60 (18) 30 (11) 29 (16) 229 (16)
None 94 (28) 102 (30) 87 (26) 73 (28) 58 (31) 414 (28)
 
Baseline medical diagnoses — no. (%)
 
Diabetes (type 1 or 2) 36 (11) 40 (12) 32 (9) 29 (11) 17 (9) 154 (11)
Hyperlipidemia 56 (17) 44 (13) 42 (12) 36 (14) 26 (14) 204 (14)
Hypertension 68 (20) 67 (20) 63 (18) 60 (23) 31 (17) 289 (20)
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P=0.013) and was significantly longer in the risperi-
done group than in the quetiapine group (hazard
ratio, 0.77; P=0.021).
 
adjustment of outcomes for covariates
 
An exploratory analysis identified the following
predictors of an earlier time to discontinuation:
higher baseline PANSS score (P=0.001), younger
age (P<0.001), longer duration since the first use
of antipsychotic medication (P=0.057), and the an-
tipsychotic drug taken before study entry (P=0.001).
Baseline antipsychotic agents were grouped into six
categories (Table 1). Patients receiving olanzapine
or risperidone before enrollment stayed in phase 1
of the trial longer than those taking no antipsychot-
ic agents, those taking combination treatments, or
those receiving a single antipsychotic agent exclud-
ing olanzapine, quetiapine, or risperidone; pair-
wise hazard ratios ranged from 0.68 (P<0.001) to
0.80 (P<0.02). No interactions with treatment group
were significant at a P value of less than 0.10. After
adjustment for these predictors of discontinuation,
the results of treatment-group comparisons were




Total PANSS scores improved over time in all groups
(Fig. 2). The mixed model revealed significant vari-
 
Figure 1. Enrollment and Outcomes.
 
Patients with tardive dyskinesia were not assigned to perphenazine. Ziprasidone was added to the study after approximately 40 percent 




   quetiapine
    8 Did not take drug
341 Assigned to
   risperidone
    8 Did not take drug
185 Assigned to
   ziprasidone
    2 Did not take drug
261 Assigned to
   perphenazine
    4 Did not take drug
336 Assigned to
   olanzapine
    6 Did not take drug
329 Included in analysis 333 included in analysis 183 Included in analysis257 Included in analysis330 Included in analysis
60 (18%) Completed
       phase 1
269 (82%) Discontinued
quetiapine
92 For lack of efficacy
49 Owing to intoler-
ability
109 Owing to patient’s
decision





91 For lack of efficacy
34 Owing to intoler-
ability
101 Owing to patient’s
decision





44 For lack of efficacy
28 Owing to intoler-
ability
63 Owing to patient’s
decision
10 For other reasons
65 (25%) Completed
       phase 1
192 (75%) Discontinued
perphenazine
65 For lack of efficacy
40 Owing to intoler-
ability
77 Owing to patient’s
decision
10 For other reasons
120 (36%) Completed
       phase 1
210 (64%) Discontinued
olanzapine
48 For lack of efficacy
62 Owing to intoler-
ability
78 Owing to patient’s
decision
22 For other reasons
401 Excluded
124 Did not meet study criteria
109 Declined
  33 Decided against changing
       antipsychotic agent
135 Had other reasons
All 33 patients from one site
excluded before analysis
because of concern about
integrity of the data
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ation in treatment effects over time (P=0.002). Im-
provement was initially greatest in the olanzapine
group, but its advantage diminished over time. The
pattern of change in the scores for the CGI Scale
was similar to that for the PANSS scores (P=0.004




The rates of adverse events and side effects are list-
ed in Table 3. Fewer patients in the olanzapine group
than in the other four groups were hospitalized for
an exacerbation of schizophrenia (11 percent vs. 15
to 20 percent, P<0.001). After adjustment for the
different durations of treatment, the olanzapine
group had a risk ratio for hospitalization of 0.29 per
person-year of treatment, as compared with risk
ratios of 0.45 to 0.66 in the other groups.
The rates of treatment discontinuation due to
intolerable side effects differed between treatments
(P=0.04). Risperidone had the lowest rate (10 per-
cent), and olanzapine had the highest rate (18 per-
cent). Moreover, more patients discontinued olan-
zapine owing to weight gain or metabolic effects
(9 percent vs. 1 percent to 4 percent with the other
four drugs, P<0.001) and more patients discontin-
ued perphenazine owing to extrapyramidal effects
(8 percent vs. 2 percent to 4 percent, P=0.002).
Patients in the olanzapine and quetiapine groups
had lower rates of insomnia (16 and 18 percent, re-
spectively) than did patients in the other groups (24
percent in the risperidone group, 25 percent in the
perphenazine group, and 30 percent in the ziprasi-
done group). Quetiapine was associated with a high-
er rate of anticholinergic effects than were the other




There were no significant differences among the
groups in the incidence of extrapyramidal side ef-
fects, akathisia, or movement disorders as reflected
by rating-scale measures of severity.
 
Weight Gain and Metabolic Changes
 
Patients in the olanzapine group gained more
weight than patients in any other group, with an av-
erage weight gain of 2 lb (0.9 kg) per month. A larger
proportion of patients in the olanzapine group than
in the other groups gained 7 percent or more of their
baseline body weight (30 percent vs. 7 to 16 percent,
P<0.001).
Olanzapine had effects consistent with the po-
tential development of the metabolic syndrome and
was associated with greater increases in glycosylat-
ed hemoglobin, total cholesterol, and triglycerides
after randomization than the other study drugs,
even after adjustment for the duration of treat-
ment. Ziprasidone was the only study drug associ-
ated with improvement in each of these metabolic
variables. Only risperidone was associated with a
substantial increase in prolactin levels.
 
Other Potential Adverse Events
 
There were no substantially different effects of the
medications on the corrected QT interval on elec-
trocardiography, and torsades de pointes did not
develop in any patients. There were no significant
differences among the groups in the incidence of
new cataracts. There were no significant differences
among the groups in the rates of suicide attempts





There were few substantial differences among the
groups in the rates or types of medications added
during the study. Patients in the olanzapine and ris-
peridone groups were the least likely to have anxio-
lytic agents added (9 and 10 percent, respectively,
vs. 14 to 15 percent). Fewer patients receiving que-
tiapine were prescribed anticholinergic drugs (3 per-
cent vs. 8 to 10 percent).
All second-generation antipsychotic drugs were in-
cluded in phase 1 of this study except aripiprazole
(which was approved by the FDA in November
2002) and clozapine, which was included in phase 2
for patients who discontinued phase 1 of treatment
owing to lack of efficacy of the assigned drug. Al-
though haloperidol is the first-generation agent
most commonly used for comparison, we chose to





Only a minority of patients in each group took
their assigned drug for the duration of phase 1 (rates
of discontinuation ranged from 64 to 82 percent).
This outcome indicates that antipsychotic drugs,
though effective, have substantial limitations in
their effectiveness in patients with chronic schizo-
phrenia. Although the rates of discontinuation may
have been increased by the fact that patients were
participating in a blinded, controlled trial, the rates
are generally consistent with those previously ob-
discussion
Copyright © 2005 Massachusetts Medical Society. All rights reserved. 



















































































Mean modal dose — mg per day/total no. of patients 20.1/312 543.4/309 3.9/305 20.8/245 112.8/165 
Maximal dose received — no. of patients (%) 124/312 (40) 137/309 (44) 122/305 (40) 98/245 (40) <0.001 80/165 (48)
 
Discontinuation of treatment for any cause
 
Discontinuation — no. of patients (%) 210 (64) 269 (82) 245 (74) 192 (75) 145 (79)
Kaplan–Meier time to discontinuation — mo
Median (95% CI) 9.2 (6.9–12.1) 4.6 (3.9–5.5) 4.8 (4.0–6.1) 5.6 (4.5–6.3) 3.5 (3.1–5.4)
Cox-model treatment comparisons¿
Olanzapine
Hazard ratio (95% CI)  0.63 (0.52–0.76) 0.75 (0.62–0.90) 0.78 (0.63–0.96) 0.004** 0.76 (0.60–0.97)
P value <0.001** 0.002** 0.021 0.028
Quetiapine
Hazard ratio (95% CI) 1.19 (0.99–1.42) 1.14 (0.93–1.39) 1.01 (0.81–1.27)
P value 0.06 0.21 0.94
Risperidone
Hazard ratio (95% CI) 1.00 (0.82–1.23) 0.89 (0.71–1.14)
P value 0.99 0.36
Perphenazine
Hazard ratio (95% CI) 0.90 (0.70–1.16)
P value 0.43
 
Discontinuation of treatment for lack of efficacy
 
Discontinuation — no. of patients (%) 48 (15) 92 (28) 91 (27) 65 (25) 44 (24)
Kaplan–Meier time to discontinuation — mo
25th percentile (95% CI) —†† 6.0 (4.5–8.0) 6.0 (4.4–9.0) 6.1 (4.5–9.1) 6.9 (3.2–12.1)
Cox-model treatment comparisons¿
Olanzapine
Hazard ratio (95% CI) 0.41 (0.29–0.57) 0.45 (0.32–0.64) 0.47 (0.31–0.70) <0.001** 0.59 (0.37–0.93)
P value <0.001** <0.001** <0.001** 0.026
Quetiapine
P value 0.49 0.47 0.69
Risperidone




Discontinuation of treatment owing to intolerability‡‡
 
Discontinuation — no. (%) 62 (19) 49 (15) 34 (10) 40 (16) 28 (15) 
Cox-model treatment comparisons¿
Risperidone
Hazard ratio (95% CI) 0.62 (0.41–0.95) 0.65 (0.42–1.00) 0.60 (0.36–0.98) 0.054 0.79 (0.46–1.37)
P value 0.027 0.051 0.043 0.41
Olanzapine
P value 0.84 0.49 0.28
Quetiapine
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* CI denotes confidence interval.
† Patients with tardive dyskinesia were excluded from the perphenazine group.
‡ The overall P value is for the comparison of olanzapine, quetiapine, risperidone, and perphenazine with the use of a 3 df test from a Cox model for survival outcomes, excluding patients 
with tardive dyskinesia. If the difference among the groups was significant at a P value of less than 0.05, the three atypical agents were compared with each other by means of step-down 
or closed testing to identify significant differences (P<0.05) between groups. Each atypical agent was then compared with perphenazine by means of a Hochberg adjustment. The small-
est P value for the perphenazine group was compared with a value of 0.017 (0.05÷3). 
§ Statistical analyses involving the ziprasidone group were confined to the cohort of patients who underwent randomization after ziprasidone was added to the study, with the use of a 
Hochberg adjustment for four pairwise comparisons. The smallest P value was compared with a value of 0.013 (0.05÷4). 
¶ The modal dose and percentages of patients taking the maximal dose are based on the number of patients with data on the dose. Information on dose was not available for some pa-
tients who dropped out early. The P values for the percentage of patients reaching the maximal dose were calculated with the use of a 4 df test comparing all treatment groups from a 
Poisson regression accounting for differential exposure times, and adjusting for whether the patient had had an exacerbation in the preceding three months. 
¿ For pairwise comparisons of treatment groups, Cox-model hazard ratios of less than 1 indicate a greater time to the discontinuation of the first treatment listed.
** P value is statistically significant.
†† The Kaplan–Meier 25th percentile for discontinuation owing to lack of efficacy could not be estimated for olanzapine because of the low event rates.
‡‡ The Kaplan–Meier 25th percentile for discontinuation owing to intolerability could not be estimated because of the low event rates.
§§ This category includes decisions made by both patients and their advocates.
 
¶¶ Successful treatment was defined by a CGI severity score of at least 3 (mildly ill) or by a score of 4 (moderately ill) with an improvement of at least two points from baseline.
 
Patient’s decision to discontinue treatment§§
 
Discontinuation — no. (%) 78 (24) 109 (33) 101 (30) 77 (30) 63 (34) 
Kaplan–Meier time to discontinuation — mo
25th percentile (95% CI) 12.3 (8.0–17.8) 4.9 (3.1–7.0) 4.5 (3.1–8.8) 6.2 (4.7–8.1) 3.4 (3.0–6.1)
Cox-model treatment comparisons¿
Olanzapine
Hazard ratio (95% CI) 0.56 (0.42–0.75) 0.67 (0.50–0.90) 0.70 (0.50–0.98) 0.034** 0.63 (0.43–0.93)
P value <0.001** 0.008** 0.036 0.018
Quetiapine
P value 0.21 0.46 0.63
Risperidone




Duration of successful treatment¶¶
 
Kaplan–Meier time to discontinuation — mo
Median (95% CI) 3 (2–5) 1 (0–1) 1 (0–1) 1 (1–2) 1 (0–1) 
Cox-model treatment comparisons¿
Olanzapine
Hazard ratio (95% CI) 0.53 (0.43–0.67) 0.69 (0.55–0.87) 0.73 (0.57–0.93) <0.001** 0.75 (0.58–0.94)
P value <0.001** 0.002** 0.013** 0.017
Quetiapine
Hazard ratio (95% CI) 1.30 (1.04–4.63) 1.28 (1.00–1.64) 1.06 (0.85–1.33)
P value 0.02** 0.05 0.61
Risperidone
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Figure 2 (facing page). Outcome Measures of Effec-
tiveness.
 
The number of patients included at each assessment time 
point declined over time. Estimates are from a mixed 
model, which assumed that data were missing at random. 
Scores for the PANSS and CGI Scale were determined at 
study entry and 1, 3, 6, 9, 12, 15, and 18 months after ran-
domization. Scores for the PANSS can range from 30 to 
210, with higher scores indicating more severe psycho-
pathology. Scores for the CGI Scale can range from 1 to 7, 
with higher scores indicating a greater severity of illness. 
Analyses involving the ziprasidone group were limited to 
the cohort of patients who underwent randomization after 
the addition of ziprasidone to the study (the ziprasidone 
cohort). Thus, the P value for the overall interaction be-
tween time and treatment excludes the ziprasidone group 






 Within this limited range of effectiveness,
the olanzapine group had the lowest rate of discon-
tinuation, which might lead one to consider olan-
zapine the most effective of the medications stud-
ied. Its apparent superior efficacy is also indicated
by the greater reduction in psychopathology, longer
duration of successful treatment, and lower rate of
hospitalizations for an exacerbation of schizophre-
nia. The results for the other second-generation
antipsychotic agents and the representative con-
ventional drug, perphenazine, were similar in most
respects. It is important to note that the differences
between olanzapine and perphenazine were mod-
erate. Although there were no significant differ-
ences in the time until discontinuation owing to
intolerable side effects, there were differences in
rates. Moreover, olanzapine was associated with
greater increases in weight and indexes of glucose
and lipid metabolism than the other treatments.
Dose could have been a factor in the performance
of the various agents studied. The dose ranges ap-
proved by the FDA for quetiapine and ziprasidone
may be below their optimal therapeutic doses,
and the recommended doses of risperidone (6 mg
per day or less), intended to limit extrapyramidal





 However, the dose ranges we used
were based on information from the manufacturer
of each medication plus knowledge of clinical prac-
tice patterns. Moreover, the average prescribed dos-
es of these drugs in the United States for patients
with schizophrenia during the period in which the
study was conducted (14 mg of olanzapine per day,
3.8 mg of risperidone per day, 388 mg of quetia-
pine per day, and 125 mg of ziprasidone per day)





fact that a higher proportion of patients assigned to
quetiapine and ziprasidone received the maximal
dose allowed in the study suggests that these agents
are either less effective or require higher doses (Ta-
ble 2). The dose range of perphenazine was chosen
to minimize the potential for extrapyramidal symp-
toms that may have biased previous comparisons of




The use of low-dose perphenazine appears to
have diminished the frequency of extrapyramidal
side effects in patients who received the first-gener-





portion of patients with extrapyramidal symptoms
did not differ significantly among those who re-
ceived first-generation and second-generation drugs
in our study. Despite this finding, more patients dis-
continued perphenazine than other medications ow-
ing to extrapyramidal effects.
As in other studies, we found that risperidone
was associated with hyperprolactinemia and olan-
zapine was associated with substantial weight gain
in addition to adverse changes in glucose and lipid
metabolism — all features of the metabolic syn-
drome. Concerns about potential prolongation of
the corrected QT interval with ziprasidone and of
cataracts with quetiapine were not realized in this
study.
We used broad inclusion and minimal exclu-
sion criteria and allowed the enrollment of patients
with coexisting conditions and those who were tak-
ing other medications. The study was conducted in
a variety of clinical settings in which people with
schizophrenia are treated. These “real-world” fea-
tures of the study, which were intended to make the
results widely applicable, may account for the dif-
ferences in results between this and previous stud-
ies comparing first- and second-generation anti-
psychotic agents.
In summary, patients with chronic schizophre-
nia in this study discontinued their antipsychotic
study medications at a high rate, indicating sub-
stantial limitations in the effectiveness of the drugs.
Within this limited range of effectiveness, olanza-
pine appeared to be more effective than the other
drugs studied, and there were no significant dif-
ferences in effectiveness between the conventional
drug perphenazine and the other second-genera-
tion drugs. There were no significant differences
among the drugs in the time until discontinuation
of treatment owing to intolerable side effects. How-
ever, olanzapine was associated with greater weight
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Hospitalization for exacerbation of schizophrenia
 
Hospitalized patients — no. (%) 38 (11) 68 (20) 51 (15) 41 (16) 33 (18) <0.001
No. of hospitalizations/total person-yr of exposure 81/280 131/199 103/229 89/175 62/109
Risk ratio 0.29 0.66 0.45 0.51 0.57
 
Adverse events — no. (%)
 
Any serious adverse event 32 (10) 32 (9) 33 (10) 29 (11) 19 (10) 0.47
Suicide attempt 2 (<1) 1 (<1) 2 (<1) 1 (<1) 1 (<1) 0.99
Suicidal ideation 1 (<1) 2 (<1) 4 (1) 3 (1) 2 (1) 0.49
Any moderate or severe adverse event identified by 
systematic inquiry
235 (70) 220 (65) 232 (68) 170 (65) 119 (64) 0.14
Insomnia 55 (16) 62 (18) 83 (24) 66 (25) 56 (30) <0.001
Hypersomnia, sleepiness 104 (31) 103 (31) 96 (28) 74 (28) 45 (24) 0.18
Urinary hesitancy, dry mouth, constipation 79 (24) 105 (31) 84 (25) 57 (22) 37 (20) <0.001
Decreased sex drive, arousal, ability to reach orgasm 91 (27) 69 (20) 91 (27) 64 (25) 35 (19) 0.59
Gynecomastia, galactorrhea 7 (2) 6 (2) 14 (4) 4 (2) 6 (3) 0.15
Menstrual irregularities‡ 11 (12) 5 (6) 16 (18) 7 (11) 8 (14) 0.17
Incontinence, nocturia 18 (5) 15 (4) 25 (7) 6 (2) 10 (5) 0.04
Orthostatic faintness 31 (9) 38 (11) 37 (11) 29 (11) 24 (13) 0.08
Any moderate or severe spontaneously reported 
adverse event
122 (36) 113 (34) 123 (36) 79 (30) 65 (35) 0.10
 
Neurologic effects — no./total no. (%)§
 
AIMS global severity score ≥2 32/236 (14) 30/236 (13) 38/238 (16) 41/237 (17) 18/126 (14) 0.23
Barnes Akathisia Rating Scale global score ≥3 15/290 (5) 16/305 (5) 20/292 (7) 16/241 (7) 14/158 (9) 0.24
Simpson–Angus Extrapyramidal Signs Scale mean 
score ≥1 
23/296 (8) 12/298 (4) 23/292 (8) 15/243 (6) 6/152 (4) 0.47
 
Discontinuation of treatment owing to intolerability — no. %
 
Discontinuation 62 (18) 49 (15) 34 (10) 40 (15) 28 (15) 0.04
Weight gain or metabolic effects 31 (9) 12 (4) 6 (2) 3 (1) 6 (3) <0.001
Extrapyramidal effects 8 (2) 10 (3) 11 (3) 22 (8) 7 (4) 0.002
Sedation 7 (2) 9 (3) 3 (1) 7 (3) 0 0.10
Other effects 16 (5) 18 (5) 14 (4) 8 (3) 15 (8) 0.16
 
Weight change from baseline to last observation¶
 
Weight gain >7% — no./total no. (%) 92/307 (30) 49/305 (16) 42/300 (14) 29/243 (12) 12/161 (7) <0.001
Weight change — lb
Mean ±SE 9.4±0.9 1.1±0.9 0.8±0.9 ¡2.0±1.1 ¡1.6±1.1 <0.001
Median 7 1 0 ¡1 ¡2
Range ¡14 to 42 ¡25 to 25 ¡24 to 24 ¡29 to 22 ¡24 to 18
Weight change — lb/mo of treatment
Mean ±SE 2.0±0.3 0.5±0.2 0.4±0.3 ¡0.2±0.2 ¡0.3±0.3 <0.001
Median 0.8  0.1  0.0  ¡0.1 ¡0.3
Range ¡1.4 to 9.5 ¡4.4 to 6.3 ¡4.6 to 5.7 ¡4.9 to 4.0 ¡5.3 to 5.9
 
Change from baseline in laboratory values¿
 
Blood glucose — mg/dl
Mean ±SE 15.0±2.8 6.8±2.5 6.7±2.0 5.2±2.0 2.3±3.9
Median 7.0 4.3 5.5 1.5 2.5
Exposure-adjusted mean ±SE 13.7±2.5 7.5±2.5 6.6±2.5 5.4±2.8 2.9±3.4 0.59
Glycosylated hemoglobin — %
Mean ±SE 0.41±0.09 0.05±0.05 0.08±0.04 0.10±0.06 ¡0.10±0.14
Median 0.20 0.10 0.05 0.05 0.10
Exposure-adjusted mean ±SE 0.40±0.07 0.04±0.08 0.07±0.08 0.09±0.09 0.11±0.09 0.01
Cholesterol — mg/dl
Mean ±SE 9.7±2.1 5.3±2.1 ¡2.1±1.9 0.5±2.3 ¡9.2±5.2
Median 8.5 3.5 ¡3.0 0.5  ¡1.0
Exposure¡adjusted mean ±SE 9.4±2.4 6.6±2.4 ¡1.3±2.4 1.5±2.7 ¡8.2±3.2 <0.001
Triglycerides — mg/dl
Mean ±SE 42.9±8.4 19.2±10.6 ¡2.6±6.3 8.3±11.5 ¡18.1±9.4
Median 33.5 17.5 3.0 2.0 ¡7.0
Exposure-adjusted mean ±SE 40.5±8.9 21.2±9.2 ¡2.4±9.1 9.2±10.1 ¡16.5±12.2 <0.001
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* Patients with tardive dyskinesia were excluded from the perphenazine group.
† P values, presented for descriptive purposes, are from a test with 4 df comparing all treatment groups. P values for reasons of discontinua-
tion are from a chi-square test. P values for percentages are from a Poisson regression accounting for differential exposure times and adjust-
ing for whether the patient had had an exacerbation in the preceding three months. P values for a prolonged corrected QT interval and new 
cataracts are from Fisher’s exact test. P values for laboratory values are based on a ranked analysis of covariance with adjustment for whether 
the patient had had an exacerbation in the preceding three months and the duration of exposure to the study drug during phase 1. P values 
for the change in weight and the corrected QT interval are based on an analysis of covariance with adjustment for whether the patient had 
had an exacerbation in the preceding three months and the duration of exposure to study drug during phase 1.
‡ Percentages are based on the number of female patients: 92 in the olanzapine group, 82 in the quetiapine group, 88 in the risperidone group, 
62 in the perphenazine group, and 56 in the ziprasidone group.
§ Scores of 2 or more on the Abnormal Involuntary Movement Scale (AIMS) global severity score indicate at least mild severity of abnormal 
movements. Percentages are based on the number of patients without tardive dyskinesia who had an AIMS score of less than 2 at baseline 
and at least one post-baseline measurement. Scores of 3 or more for the global clinical assessment of the Barnes Akathisia Rating Scale in-
dicate at least moderate severity of akathisia. Percentages are based on the number of patients who had a Barnes score of less than 3 at baseline 
and at least one post-baseline measurement. Average scores of 1 or more for the Simpson–Angus Extrapyramidal Signs Scale indicate at 
least mild severity of extrapyramidal signs. Percentages are based on the number of patients who had an average score for the Simpson–
Angus Extrapyramidal Signs Scale of less than 1 at baseline and at least one post-baseline measurement.
¶ Percentages for weight gain are based on the number of patients with a baseline and at least one post-baseline measurement. To convert val-
ues for weight to kilograms, divide by 2.2. The range for weight change is the 5th to 95th percentile, which excludes extreme outliers.
¿ Patients were instructed to fast; nonfasting results were not excluded. Change was determined as the difference between the baseline value 
and the average of the two highest post-baseline values. The exposure-adjusted mean is the least-squares mean from an analysis of co-
variance adjusting for whether the patient had had an exacerbation in the preceding three months and for duration of exposure to study 
drug during phase 1. Since the measurement of glycosylated hemoglobin was added to the protocol as part of a protocol amendment, the 
numbers of patients are smaller for this test: 151 in the olanzapine group, 137 in the quetiapine group, 139 in the risperidone group, 107 
in the perphenazine group, and 89 in the ziprasidone group. The analysis of all other laboratory variables included 286 patients in the olan-
zapine group, 268 in the quetiapine group, 262 in the risperidone group, 212 in the perphenazine group, and 143 in the ziprasidone group. 
To convert values for blood glucose to millimoles per liter, multiply by 0.05551. To convert values for cholesterol to millimoles per liter, mul-
tiply by 0.02586. To convert values for triglycerides to millimoles per liter, multiply by 0.01129.
** Percentages are based on the number of patients who had a normal corrected QT interval at baseline (450 msec or less for men and 470 
msec or less for women) and at least one post-baseline measurement.
††Percentages are based on the number of patients with a post-baseline assessment.
‡‡Percentages are based on the number of patients with data available: 333 in the olanzapine group, 333 in the quetiapine group, 340 in the ris-
peridone group, 259 in the perphenazine group, and 184 in the ziprasidone group.
















Change from baseline in laboratory values¿ (cont.)
 
Prolactin — ng/dl
Mean ±SE ¡6.1±1.2 ¡9.3±1.4 15.4±1.5 0.4±1.7 ¡4.5±1.6
Median ¡0.9 ¡2.7 9.2 1.4 ¡2.4




Mean (±SE) change in corrected QT interval from base-
line to last observation — msec
1.2±1.8 5.9±1.9 0.2±1.8 1.4±2.0 1.3±2.2 0.25
Prolonged corrected QT interval — no./total no. (%) 0/231 6/214 (3) 7/218 (3) 2/172 (1) 2/148 (1) 0.03
 
New cataracts — no./total no. (%)††
 
3/272 (1) 1/258 (<1) 2/260 (1) 1/210 (<1) 0/142 0.81
 
Medications added — no. (%)‡‡
Lithium 1 (<1) 4 (1) 2 (<1) 3 (1) 1 (<1) 0.42
Anticonvulsants 10 (3) 11 (3) 13 (4) 9 (3) 8 (4) 0.63
Antidepressants§§ 40 (12) 28 (8) 54 (16) 28 (11) 26 (14) 0.03
Hypnotics, sedatives¶¶ 22 (7) 14 (4) 32 (9) 23 (9) 17 (9) 0.03
Anxiolytics 31 (9) 46 (14) 33 (10) 38 (15) 27 (15) <0.001
Anticholinergic agents 25 (7) 11 (3) 32 (9) 26 (10) 14 (8) 0.01
Oral glucose-lowering drugs, insulin 12 (4) 7 (2) 8 (2) 5 (2) 4 (2) 0.95
Cholestatin drugs 15 (4) 14 (4) 11 (3) 7 (3) 2 (1) 0.28
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gain and increases in glycosylated hemoglobin,
cholesterol, and triglycerides, changes that may have
serious implications with respect to medical comor-
bidity such as the development of the metabolic
syndrome. How clinicians, patients, families, and
policymakers evaluate the trade-offs between effi-
cacy and side effects, as well as drug prices, will de-
termine future patterns of use.
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